LMTK2 as Potential Biomarker for Stratification between Clinically Insignificant and Clinically Significant Prostate Cancer

Table 1

Clinical characteristics of control subjects relative to clinical characteristics of both BPD and PC and clinical characteristics of ciPC relative to clinical characteristics of csPC.

Line no.	Characteristics	Control (N = 20)	BPD (N = 96)	PC (N = 104)	value	ciPC (N = 54)	csPC (N = 50)	value
1	Median age, yr, IQR	61, 12.6	64.8, 8.5	65.4, 8.0	0.11	65.4, 8.5	65.6, 8.6	0.71
2	Median PSA I level, first test, ng/ml, IQR	5.3, 4.2	4.7, 1.8	4.9, 2.3	0.74	4.8, 2.1	5.3, 3.8	0.12
3	Median PSA II level, last test, ng/ml, IQR	7.4, 4.7	7.5, 4.7	8.0, 6.3	0.56	7.9, 6.4	9.1, 6.9	0.19
4	Median difference between PSA II and PSA I, IQR	1.66, 3.3	2.58, 3.18	2.54, 3.70	0.52	2.29, 3.08	2.95, 4.06	0.54
5	Median PSA density, ng/ml	0.07, 0.09	0.09, 0.06	0.15, 0.14	<0.001	0.13, 0.1	0.21, 0.15	0.01
6	Gleason score	—	—	80, 24	—	54, 0	26, 24	<0.001 chi^2
	3 + 3
	≥3 + 4
7	Median MCCL, mm, IQR	—	—	3.0, 5.0	—	1.0, 1.6	6.0, 4.0	<0.001

Data were analysed by Kruskal–Wallis ANOVA test for control subjects, BPD, and PC independent samples. Data were analysed by Mann–Whitney U test test for ciPC and csPC independent samples unless otherwise stated. chi², chi-square test; N, group size; IQR, interquartile range.